Strategic Partnerships Leverage recent SGD Pharma collaboration to position Prince as a preferred in North American sterilization and primary packaging partner, focusing on ready-to-use Type I glass vials and nasal platforms to win pharma and biotech customers seeking integrated supply chain solutions.

Expansion Signals capitalize on announced US market launches and R&D activity around sterile nasal vials and My Sterinity platform to target pharmaceutical companies developing chronic condition therapies that require reliable sterile packaging, increasing outreach to device and pharma manufacturers with complex aseptic needs.

Technology Differentiation Promote in-house capabilities in moist heat, dry heat, depyrogenation, and WFI washing, plus low-temperature hydrogen peroxide sterilization, to address customers looking to consolidate sterility workflow under one provider and reduce bioburden and endotoxin risk.

Quality and Compliance Highlight USP-grounded WFI testing and clean-room processing as a differentiator for regulated environments, targeting pharma and medical device firms prioritizing compliant sterilization, packaging, and integrity testing for high-value sterile products.

Growth and Investment Leverage the funding/partnership momentum with Vance Street Capital and recognition as contract sterilization service of the year to engage growth-minded manufacturers seeking scalable sterilization and packaging capacity, offering co-development and manufacturing expansion discussions.